Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. CRWD
4. RXRX
5. ON
6. VRTX
7. INSP
8. CVI
9. CHKP
10. MPC

Go back to Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance

Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance

February 27, 2019 7:00 AM EST

-- Fourth-Quarter 2018 Net Sales Increased 30 Percent to $355.5 Million Driven by 33 Percent Growth in Orphan and Rheumatology Segment;
Fourth-Quarter 2018 GAAP Net Income of $87.6 Million; Adjusted EBITDA of $151.1 Million --

-- Full-Year 2018 Net Sales Increased 14 Percent to $1.21 Billion Driven by 22 Percent Growth in Orphan and Rheumatology Segment;
Full-Year 2018 GAAP Net Loss of $74.2 Million; Adjusted EBITDA of $451.4 Million --

-- Full-Year Orphan and Rheumatology Segment Net Sales of $831.5 Million
Representing Approximately 70 Percent of Total Company Full Year Net Sales;
Segment Operating Income of $290.0 Million --... More